Outcome of Different Therapeutic Interventions in Mild COVID-19 Infection
Sayak Roy1*, Shambo Samrat Samajdar2, Santanu K Tripathi3, Shatavisa Mukherjee4, Kingshuk Bhattacharjee5
Journal Title: Journal of Clinical Immunology AND Microbiology
Background: Coronavirus disease 2019 (COVID-19) case and the death toll has reached milestones of over 12,28,22,505 and 27,09,041 respectively worldwide as of 22nd March 2021. Treatment regimens are cropping up daily and adding up to the dilemma of the treating physicians.
Aims: This present study aimed to see the Clinical Response of Well-Being (CRWB) reporting time in mild COVID-19 infected patients after their treatment initiation in four different treatment arms.
Methods: A total of 56 patients meeting the case definition of mild COVID-19 infection were included after the retrospective screening of the investigators’ electronic database. Patients were divided into four groups – Hydroxychloroquine (HCQ) taking group, patients on the combination of Doxycycline (DOX) + Ivermectin (IVR), Azithromycin (AZ) taking group and symptomatic treatment receiving group.
Results: There was no difference in CRWB between the four groups (p-value 0.846). The group on symptomatic management arm showed significant correlation between CRP (p-value 0.01), LDH (p-value 0.001), and age (p-value 0.035) with CRWB. Significant correlation was also seen between blood levels of CRP (p-value 0.03), LDH (p-value 0.001) and D-dimer (p-value 0.04) with CRWB in the IVR+DOX group.
Conclusion: No specific drug treatment is required to treat mild COVID-19 infection other than symptomatic management in patients with a low risk of progression.